Next-level medicine with ease.

Next-level medicine
with ease.

We are a clinical-stage biopharmaceutical company unlocking difficult-to-produce biologics based on a transformative manufacturing platform.


Developing unique medicines for patients.


Two innovative therapies for orphan diseases.


Smart biologics enabled by moss.


A unique opportunity in complement
disorders: Factor H (CPV-104)

Eleva’s team combines decades of scientific and industry experience. We relentlessly pursue those therapeutic opportunities, where our technology and expertise can make a key difference and deliver next-level medicines to patients.

  • Dr. Henrik Luessen
    Chief Business Officer (external)
  • Danielle Püschel
    Chief Financial Officer
  • Karin Heidenreich, M.Sc.
    Senior Director Clinical Program
  • Björn Cochlovius, Ph.D., Assoc. Prof.
    Chief Executive Officer & Managing Director

Eleva will be at the forefront of unlocking unique biological therapies with an equally unique expression platform. Stay up to date on our progress to learn more about how Eleva can change patient’s lives and help forge therapies that might otherwise be neglected.

  • Oct 17, 2024 dedicated to pediatric case reports and Eleva’s Factor H (CPV-104) study program.

Stay in the loop and subscribe Eleva’s newsletter


Eleva offers a workplace that is focused on a valuable goal – bringing unique therapies to patients in need.

Next Page